share_log

Exicure | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)

Exicure | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)

Exicure | SC 13D/A:超過5%持股股東披露文件(修正)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)
美股sec公告 ·  07/02 18:15
Moomoo AI 已提取核心訊息
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a recent Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated June 28, 2024, is an amendment (Amendment No. 12) to a series of previous amendments and the initial Schedule 13D filed on June 1, 2022. This latest amendment involves two reporting persons, CBI USA, Inc., and DGP Co., Ltd., both of which have disclosed significant ownership stakes in Exicure. CBI USA, Inc., a Delaware-based entity, reported owning 818,299 shares, representing 9.5% of the company, while DGP Co., Ltd., based in the Republic of Korea, reported a substantial holding of 3,060,000 shares, amounting to 35.4% of Exicure. The amendment also details contractual arrangements, including an extension of the closing date for the balance of the DGP Sale to July 31, 2024, and an extension of the settlement date for a Stock Loan to December 31, 2024. The filing was certified by Kyungwon Oh, the Chief Executive Officer of both CBI USA, Inc. and DGP Co., Ltd.
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a recent Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated June 28, 2024, is an amendment (Amendment No. 12) to a series of previous amendments and the initial Schedule 13D filed on June 1, 2022. This latest amendment involves two reporting persons, CBI USA, Inc., and DGP Co., Ltd., both of which have disclosed significant ownership stakes in Exicure. CBI USA, Inc., a Delaware-based entity, reported owning 818,299 shares, representing 9.5% of the company, while DGP Co., Ltd., based in the Republic of Korea, reported a substantial holding of 3,060,000 shares, amounting to 35.4% of Exicure. The amendment also details contractual arrangements, including an extension of the closing date for the balance of the DGP Sale to July 31, 2024, and an extension of the settlement date for a Stock Loan to December 31, 2024. The filing was certified by Kyungwon Oh, the Chief Executive Officer of both CBI USA, Inc. and DGP Co., Ltd.
在納斯達克股票代碼爲XCUR的生物技術公司Exicure,最近提交了一份13D/A報告給美國證券交易委員會(SEC)。該修正案是2022年6月1日初次提交的13D及多份之前提交的修正案之第12次修正,日期爲2024年6月28日。這份最新的修正案涉及兩個報告人,分別是CBI USA,Inc和DGP Co.,Ltd。兩位報告人披露了它們在Exicure的持股情況。總部位於德拉華的實體CBI USA,Inc.報告持有818,299股,佔公司股份的9.5%,而總部位於韓國的DGP Co.,Ltd.則報告擁有306萬股的大量持股,佔Exicure股份的35.4%。該修正案還詳細說明了包括DGP出售餘額的交割日期延長至2024年7月31日和股票貸款的結算日期延長至2024年12月31日在內的合同安排。該報告由CBI USA,Inc.和DGP Co.,Ltd.的首席執行官Oh Kyungwon簽署。
在納斯達克股票代碼爲XCUR的生物技術公司Exicure,最近提交了一份13D/A報告給美國證券交易委員會(SEC)。該修正案是2022年6月1日初次提交的13D及多份之前提交的修正案之第12次修正,日期爲2024年6月28日。這份最新的修正案涉及兩個報告人,分別是CBI USA,Inc和DGP Co.,Ltd。兩位報告人披露了它們在Exicure的持股情況。總部位於德拉華的實體CBI USA,Inc.報告持有818,299股,佔公司股份的9.5%,而總部位於韓國的DGP Co.,Ltd.則報告擁有306萬股的大量持股,佔Exicure股份的35.4%。該修正案還詳細說明了包括DGP出售餘額的交割日期延長至2024年7月31日和股票貸款的結算日期延長至2024年12月31日在內的合同安排。該報告由CBI USA,Inc.和DGP Co.,Ltd.的首席執行官Oh Kyungwon簽署。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息